Mifek Jeffrey Gerald
Chief Clinical-Medical Affairs
- Shares
- 3,125
- Price
- $3.20
- Value
- $10,000
FEMY
5 buyers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found 2 CEO/CFO purchases over 12 months.
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
+$134,000
5 buyers · 0 sellers
12-month purchases
$134,000
5 distinct insiders
12-month sales
$0.00
0 distinct insiders
Highlighted alerts
5
0 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
2 executive purchases found
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
FEMY overview: breakout setup, X sentiment and insiders in one page →
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto. Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. The reported securities were purchased by the reporting person for an aggregate amount of $10,000. The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.
Voluntary purchases and sales; administrative noise stays hidden.
Mifek Jeffrey Gerald
Chief Clinical-Medical Affairs
Sipos Jeremy Alexander
Chief Technology Officer
Canning John Charles
Chief Operating Officer
Elefant Dov
Chief Financial Officer
Lee-Sepsick Kathy
Chief Executive Officer
| Date | Insider | Transaction | Shares | Price | Value | Reading |
|---|---|---|---|---|---|---|
| Aug 07, 2026 | Mifek Jeffrey Gerald Chief Clinical-Medical Affairs | Purchase | 3,125 | $3.20 | $10,000 | |
| Aug 07, 2026 | Sipos Jeremy Alexander Chief Technology Officer | Purchase | 3,125 | $3.20 | $10,000 | |
| Aug 07, 2026 | Canning John Charles Chief Operating Officer | Purchase | 4,375 | $3.20 | $14,000 | |
| Aug 07, 2026 | Elefant Dov Chief Financial Officer | Purchase | 15,625 | $3.20 | $50,000 | |
| Aug 07, 2026 | Lee-Sepsick Kathy Chief Executive Officer | Purchase | 15,625 | $3.20 | $50,000 |
“Alert” means a voluntary, unscheduled transaction according to the filing; it is not an investment recommendation. Official source: SEC EDGAR.